

**BOOK NOW & SAVE
UP TO \$200**

June 27-28 | Pudong, Shanghai, China

www.worldadc-asia.com



Maximize the Therapeutic Index of Your ADC Candidate & Effectively Translate into the Clinic

21 Expert Speakers Include:



Xiaomai Zhou
Vice President
Research &
Development
DAC Biotech



Jianmin Fang
Professor
Tongji University



Jian Wang
Senior Principal
Scientist,
Bioanalytical Sciences
Bristol-Myers Squibb



Ron Lin
Chief Executive
Officer & Founder
AbGenomics



Shu-Hui Liu
Director
Tumor Biology
Pfizer

Lead Partner



Partners



Lonza



MabPlex 迈百瑞



Antibody Drug Conjugates **@World_ADC #World_ADC**

Tel: +1 617 455 4188 **Email:** adc@hansonwade.com



Welcome to World ADC Asia

Maximize the Therapeutic Index of Your ADC & Effectively Translate into Clinical Development

Dedicated to antibody drug conjugate drug development, World ADC Asia will curate cutting edge science and transformative insight **enabling you to effectively translate your ADC candidate into clinical development.**

Join ADC thought-leaders from **Seattle Genetics, Miracogen, Bristol-Myers Squibb** and fifteen other leading ADC organizations as they present scientifically novel ADC research whilst openly talking about their experiences.

You'll leave this meeting with the latest advances on:

- Developing novel ADC technologies to **maximize the therapeutic index of your ADC candidate**
- Filing **a successful IND to Chinese FDA and effectively translate into the clinic**
- Confidently **meeting quality specification requirements for biosimilar ADCs**

With the drug development community converging at World ADC this will be your **ultimate opportunity to catch up with familiar faces and foster new partnerships in the ADC field.**

Attend this definitive forum to exchange novel ideas, gather lessons learned and develop new partnerships to **power the next 12 months of your ADC research.**

What Previous World ADC Attendees Have Said:

Reports from the early clinical trials indicate that ADCs are setting the bar very high for eliminating cancer and the conference emphasized this exciting development **Eisai**

World ADC is the premier ADC meeting, bringing together the thought-leaders, pioneers and next generation developments that will change how we treat diseases like cancer **Research Corporation Technologies**

World ADC allows me to learn how others are innovating in the ADC field, which is simultaneously a humbling experience and an unique opportunity to expand on my own crazy ideas **Genentech**

Top 5 Reasons to Attend World ADC Asia:


1.

Explore novel payload, linker, site-specific conjugation and antibody technologies to **develop more stable and efficacious ADCs**



2.

Develop more translatable animal models, enhance your understanding of your ADC's safety profile, develop a robust analytical and bioanalytical strategy to **effectively translate into clinical development**




3.

Review the latest data from second generation ADCs, enhance your clinical trial design and dosing strategies to mitigate off-target toxicities and **maximize the therapeutic window of your candidate**



4.

Implement robust and scalable manufacturing processes, manage complex supply chains and guarantee batch to batch reproducibility to **ensure safe, efficient and cost effective manufacture of your ADC.**



5.

Learn how to **file a successful IND and meet quality specifications** for ADC and biosimilar candidates to ensure that you comply with regulation



21 Expert Speakers



Xinfang Li
Vice President
MabPlex



Baiteng Zhao
Clinical Pharmacology
Seattle Genetics



Feng Tian
Chief Scientific
Officer
Ambix



Gang Qin
President
**Genequantum
Healthcare**



Giorgio Salciarini
Technical Business
Development
Manager
**BSP
Pharmaceuticals**



Jian Wang
Senior Principal
Scientist
Bioanalytical
Sciences
**Bristol-Myers
Squibb**



Jianmin Fang
Professor
Tongji University



Jinming Gu
Vice President
Biologics
Abpro



Jinwon Jung
Principal Scientist
ABL Bio



Min Liang
Chief Scientific
Officer
TOT Biopharm



Mary Hu
Chief Executive
Officer
Miracogen



Ron Lin
Chief Executive
Officer & Founder
AbGenomics



Shu-Hui Liu
Director
Tumor Biology
Pfizer



Jeiwook Chae
Chief Business
Development Officer
**LegoChem
Biosciences**



Sunbae Lee
Antibody Drug
Conjugate Group
Leader
Alteogen



Jinkang Shen
Professor
Shanghai Institute of
Materia Medica
**Chinese Academy
of Sciences**



Tse-Wen Chang
Chief Executive
Officer & President
Immunwork



Xiaomai Zhou
Vice President
Research &
Development
DAC Biotech



Floris van Delft
Chief Scientific
Officer
Synaffix



Thomas Nittoli
Director
Chemistry
**Regeneron
Pharmaceuticals**



Hui Li
Chief Executive
Officer
Levena Biopharma


Conference Day One | Wednesday June 27

8.00 Registration & Networking

Jinkang Shen Professor, Shanghai Institute of Materia Medica Chinese Academy of Sciences	8.45 Chair's Opening Remarks
Shu-Hui Liu Director, Tumor Biology Pfizer	9.00 Keynote: Optimizing ADC Format, Target Selection & Combination Strategies to Improve Therapeutic Potential - Discover site-specific ADC conjugates tailored to different tumor types - Understand combination approaches to improve therapeutic efficacies of ADCs - Explore ADC target selection for the future
Hui Li Chief Executive Officer Levena Biopharma	9.00 Keynote: Preclinical Development of Superior ADCs Incorporating Novel Linker & Warhead Designs More details to follow
	10.00 Speed Networking This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. Use this session to get face-to-face time with many of the brightest minds working in the ADC field and establish meaningful business relationships.
	10.30 Morning Refreshments

Developing Next Generation ADC Technologies to Develop More Efficacious & Safe Candidates

Gang Qin President Genequantum Healthcare	11.00 Research & Development of Next Generation ADCs via Innovative iLDC Platform - Discover a novel bioconjugation technology to drastically improve ADCs CMC and therapeutic window - Review limitations of the current landscape of bioconjugation technologies - Drastically facilitate the CMC and enlarge the therapeutic window of ADC candidates by learning of an innovative iLDC platform - Review preclinical pipeline of next generation ADCs utilizing LDC technology
Tse-Wen Chang Chief Executive Officer & President Immunwork	11.30 ADCs with High ADR, High Targeting Valence, & Product Homogeneity - Delve into ADCs based on novel, patented multi-arm linker units - Cytotoxic drugs are prepared in "drug bundles" of multiple drug molecules and conjugated site-specifically to the targeting moiety - Targeting moiety can be IgG, IgG-like variants, or other constructs with 3 or 4 various binding elements - Modular feature is suitable for precision medicine
Jeiwook Chae Chief Business Development Officer LegoChem Biosciences	12.00 Creating Next Generation ADCs with Industry Leading DAR Precision & Plasma Stability - LCB's novel next-generation site-specific ADC platform technology - Review preclinical POC data and other key data - LCB's ADC pipelines and future development
	12.30 Lunch & Networking
Xiaomai Zhou Vice President Research & Development DAC Biotech	1.30 Development of Innovative ADCs Targeting Solid Tumors More details to follow

 Jinwon Jung Principal Scientist ABL Bio	2.00 ABL201: A BCMA-Targeting Antibody-Drug Conjugate with NTERM Conjugation for Treating Multiple Myeloma ABL201 is an MMAF-conjugated anti-BCMA ADC based on NTERM conjugation method (bullet point) NTERM is a antibody N-terminal specific conjugation method that showed improve therapeutic index when it was applied to trastuzumab (bullet point) Milder toxicity profile was observed from the single-dose rat toxicity test and an improved therapeutic index is expected
 Floris van Delft Chief Scientific Officer Synaffix	2.30 Synaffix - Session Reserved More details to follow
	3.00 Scientific Poster Session The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on novel linker designs to validation of site specific conjugation technologies and more informative <i>in vivo</i> models.
	4.00 Afternoon Refreshments & Networking
Analytical & Bioanalytical Considerations for ADCs & Biosimilars	
 Jian Wang Senior Principal Scientist, Bioanalytical Sciences Bristol-Myers Squibb	4.30 Strategies & Technologies of Analytical Characterization & Bioanalysis of ADCs - Technical challenges in ADC analytical characterization and bioanalysis - Recent advancement in technologies and strategies and an update of regulatory perspectives - Selection and correlation of various technologies and platforms in ADC bioanalysis - The trend and future: discovery and development integrated bioanalytical strategy
 Xinfang Li Vice President MabPlex	5.00 Introduction to Process Characterization on ADC Process Development - Robust manufacturing process is critical to ensure continuous and successful commercial supply for any approved drug product - Explore process characterization (PC) work including risk assessment, design and execution of PC work and establishment of control strategy for Process Performance Qualification and commercial manufacturing production - Overcome challenges of limited process development for early stage clinical supply manufacturing - Develop a robust control strategy for commercial manufacturing
 Jinming Gu Vice President Biologics Abpro	5.30 A Case Study: Discover Protein Analytics-Driven ADC Development - Gain an overview of ADC drug development - Understand how protein analytics can better inform and characterize conjugation method, linkers and payloads - Overcome challenges associated with producing and administering ADCs as a mixture of conjugated antibodies with different drug to antibody ratios (DAR) - Explore PK data for an ADC developed utilising protein analytics - Discuss the future directions of protein-analytics driven ADC development
 Tao Meng Professor, Shanghai Institute of Materia Medica Chinese Academy of Sciences	6.00 Chair's Closing Remarks

Conference Day Two | Thursday June 28

 Tao Meng Professor, Shanghai Institute of Materia Medica Chinese Academy of Sciences	9.00 Chair's Opening Remarks
 Mary Hu Chief Executive Officer Miracogen	9.05 Keynote: Preclinical Strategy for the IND Submission of MRG003 in China • Unique challenges for ADC IND filing in China • Key points to consider for ADC preclinical evaluations

Developing Robust & Scalable ADC Processes to Effectively Outsource Manufacturing

 Min Liang Chief Scientific Officer TOT Biopharm	9.35 Confidently Outsource ADC Drug Development to Chosen CMOs • Recommendations of key criteria to take into account when choosing your partner • Effectively scale up and transfer ADC development to chosen CMO • Learn how to set up and manage complex supply chain networks efficiently
 Giorgio Salciarini Technical Business Development Manager BSP Pharmaceuticals	10.05 Challenges in Scaling Up Process Development from Clinical to Commercial • Experiences when moving to higher scales and what is required to maintain process characterisation and robustness • Differences from supporting FIH to pivotal trials • Ensuring consistency of yields and process integrity during tech transfer
	10.35 Morning Refreshments & Networking

Optimization of ADCs: Maximizing the Therapeutic Window

 Jianmin Fang Professor Tongji University	11.30 RC48ADC: Optimizing Clinical Trial Design & Dosing Strategies • More details to follow
 Thomas Nittoli Director Chemistry Regeneron Pharmaceuticals	12.00 Research into Maytansinoid ADCs to Achieve Robust Therapeutics • Payload and linker development • <i>In vitro</i> screening • <i>In vivo</i> efficacy
	12.30 Lunch & Networking

Optimization of ADCs: Maximizing the Therapeutic Window

 Baiteng Zhao Clinical Pharmacology Seattle Genetics	1.30 Rational Design & Development Strategies to Overcome the Translational Challenges of ADCs • What are the critical set of attributes that dictate ADC anti-tumor activities and toxicities • Key considerations when selecting an ADC construct for a particular target and disease • Potential approaches to help guide future ADC development
---	--

 Sunbae Lee Antibody Drug Conjugate Group Leader Alteogen	2.00 ALT-P7, A Novel HER2 Targeting ADC: Enhance Development of Next Generation ADCs • Explore NexMab technology to enhance ADC clinical efficacy by increasing <i>in vivo</i> half life and potency via less frequent dosing and fewer off target toxicities • Learn how to effectively translate ADCs into the clinical development with learnings from preclinical and translational development of ALT-P7 • Review preclinical proof-of-concept data including <i>in vitro</i> binding assays and <i>in vivo</i> efficacy in animal models where ALT-P7 demonstrates superior efficacy over current drug in murine models of HER2 positive breast cancer
	2.30 Afternoon Refreshments & Networking
Exploring Next Generation ADCs in Clinical Development	
 Feng Tian Chief Scientific Officer Ambrx	3.00 Confidently Translate into Phase I Clinical Development: Explore EuCODE Technology Platform for Site- Specific Antibody Drug Conjugation • EuCODE technology platform for site-specific unnatural amino acid incorporation in mammalian cells is developed • Learn of recent efforts which have greatly improved the robustness of EuCODE technology platform • Engineer site-specific ADCs using Ambrx technology which have superior properties • Review clinical validation of site-specific ADCs • Explore the clinical data of ARX788, a HER2 targeted ADC
 Ron Lin Chief Executive Officer & Founder AbGenomics	3.30 AbGN-107: A Novel ADC for the Treatment of GI Tumors • Targeting antibody selection • Novel hydrophilic linker improves the efficacy and safety in IND enabling studies • Preliminary clinical results
	4.00 Panel Discussion: Advancing Next Generation Antibody-Drug Conjugates • Lessons learned from translating from preclinical to clinical development • Translational challenges to attaining desirable clinical therapeutic index • Analyzing clinical data for novel ADC • Overcoming challenges of bringing ADCs to market
 Tao Meng Professor, Shanghai Institute of Materia Medica Chinese Academy of Sciences	4.30 Chair's Closing Remarks

Great networking and a
very good conference
Biogen Idec



Networking Opportunities

Scientific Poster Session

Share your research with pioneers of the ADC field

Bring a scientific poster to World ADC and gain feedback on your latest research as well as share your findings to the ADC community.

Open to all, the Scientific Poster Session is one of the most popular sessions at World ADC.


Taking place during the afternoon refreshments of conference day one this data rich session is an invaluable opportunity for you to **present your own research** as well as **review scientific posters**.

All posters are subject to approval by the World ADC organisers.

Please send your abstract to adc@hansonwade.com by **Friday June 15** to be eligible.




Seniority of Attendees*



C-Level
Vice President
Global Head
Director
Manager/Project Team Leader
Scientist
Academic

Types of Attending Companies*



Large/Medium/Small Pharma
Biotech
Service Providers
Equipment Providers
Research Institute

*Based on World ADC San Diego & World ADC Berlin attendee demographics

Strong program, great speakers and a genuine focus on identifying solutions
Novartis

Companies Who Attend World ADC



Partners

Partnering with World ADC

World ADC Asia is your fastest route to organizations located in Asia prioritizing ADC development.

This inaugural meeting will bring together stakeholders and influencers across the supply chain of ADCs, from discovery through to commercial, will attend World ADC. This is your opportunity to elevate your company's standing and influence industry thinking. Your brand, your message, your reputation, showcased to the ADC community.

This could involve presenting on the agenda, hosting networking sessions, exhibiting, or brand exposure. But our focus and reach is much wider. From being fully integrated across a multi channel

global communication strategy, to targeted introductions to the right individuals in your target market, we have opportunities that offer it all.

To learn more about how we can fast-track your business to success in the ADC space contact us today at

sponsor@hansonwade.com

Lead Partner



Program Partners



Partner

Lonza

Exhibitor



|| This is an eye-opening conference that has brought together the greatest minds in antibody-drug conjugates ||

Genentech

For more information on how World ADC can support your 2018/2019 business objectives email sponsor@hansonwade.com



Curtis Dingley & Maxence Brout
Commercial Directors
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



Ready to Register?

3 Easy Ways to Book

 www.worldadc-asia.com/register

 Tel: +1 617 455 4188

 Email: adc@hansonwade.com

Top 3 Benefits of Attending

- 1 Gain lessons learned on filing a successful IND to Chinese FDA and effectively translate into the clinic
- 2 Explore novel ADC technologies to maximize the clinical therapeutic window of your ADC candidates
- 3 Confidently meet quality specification for biosimilar ADCs

Team Discounts*

- 20% discount – 5 or more delegates
- 15% discount – 4 delegates
- 10% discount – 3 delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact: register@hansonwade.com

Secure Your Place

International	Offer Ends Friday May 11	Standard Prices
Conference only	\$2199 (save \$200)	\$2399

Chinese * **	Offer Ends Friday May 11	Standard Prices
Conference only	\$899 (save \$100)	\$999

*10% WHT will be added if the company registering is a Chinese-based business

**Applicable for organizations headquartered in mainland China

Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues

Sanofi



Venue

Intercontinental Shanghai Pudong
No.777 Zhangyang Road
Pudong New Area, Shanghai
SH, 200120, Mainland China

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 9695